Chronic fatigue syndrome by Brkić Snežana et al.
256
Correspondence to:
Snežana BRKIĆ
Hospital for Infectious Diseases
Clinical Centre of Vojvodina
Hajduk Veljkova 1-9
21000 Novi Sad
Serbia
tomkis@eunet.rs
Chronic Fatigue Syndrome
Snežana Brkić, Slavica Tomić, Maja Ružić, Daniela Marić
Hospital for Infectious Diseases, Clinical Centre of Vojvodina, Novi Sad, Serbia
INTRODUCTION
Chronic fatigue syndrome (CFS) is a relatively 
poorly recognized clinical entity in medi-
cal practice, although everyday experience 
teaches us that there are many patients who 
have CFS symptoms. The unwritten rule is that 
the syndrome is associated with viral infections 
as triggers or with a protracted subfebrile condi-
tion, so that they are mostly managed by infec-
tious disease specialists, despite requiring most 
serious multidisciplinary approach.
The first records of CFS date from the 17th 
century when the syndrome was described as 
“muscle rheumatism”. Later, in the 20th century, 
it was termed military fever, exhaustion disease, 
chronic mononucleosis, chronic candidiasis, 
endemic neurasthenia, Island fever, Royal Free 
disease, Yuppie flu, etc [1, 2]. Finally, in 1988 
the Centers for Disease Control and Prevention 
(CDC) put an end to the long list of terms by 
defining precise clinical criteria for the diagno-
sis of CFS [3]. However, in different worldwide 
regions there are still other terms for the same 
condition, such as myogenic encephalomyeli-
tis and low natural killer (NK) cell syndrome 
[4, 5, 6].
Mysterious aetiopathogenesis of CFS still 
intrigues a large portion of the public which is 
best illustrated by the hundreds of studies on 
the subject published every year [6, 7]. CFS is 
now a well recognized and important health, 
as well as a socioeconomic, issue. In the USA 
alone there is an annual 9 billion dollar loss due 
to reduced productivity in people with CFS [7].
EPIDEMIOLOGY
The incidence and prevalence of CFS remains 
unknown in most countries. The largest and 
most numerous epidemiological studies come 
from the USA. The first widely publicized study 
of CFS epidemiology was initiated by the CDC 
in the late 1980’s. The prevalence rates of CFS 
were found to range from 4.0 to 8.7 individu-
als per 100,000 cases [8]. The majority of CFS 
cases were Caucasian females with medium and 
high income. Similar to other studies, a sample 
for this study was composed of patients who 
visited physicians [8, 9]. In a study conducted 
from 1995 to 1998, Jason and colleagues [8] 
screened a random sample of 18,675 subjects 
for CFS symptoms. CFS was confirmed in 
about 42% (420 per 100,000) examinees. The 
results of this study indicated that in the USA 
over 800,000 people could be affected by the 
syndrome. Middle-aged females also predom-
inated in this study, but this time they were of 
middle to lower socioeconomic status. Besides, 
about 90% of identified patients had not been 
previously diagnosed prior to the participation 
in the study nor did most of the patients ever 
visit a physician due to their problems [8, 9].
Up-to-now published studies have report ed 
very different prevalence rate of CFS. The vari-
ations are above all caused by different subject 
samples, but also by the difference in socio-
economic factors in countries where the stud-
ies have been conducted [9].
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ETHIOPATHOGENESIS
Facing the diseased disarms the superego of the conven-
tional medicine, stimulating us to return to the prime-
val conception of the man; a unique unrepeatable union 
of spirit and body. The approach to CFS cannot be exclu-
sively either psychological or physiological; on the contrary, 
it requires a wide biological and psychological consider-
ation [6].
Several hundreds of studies mention about 80 differ-
ent aetiological CFS factors which can be classified into 
five basic groups, i.e. medical fields; genetics, immunol-
ogy, infectious diseases, endocrinology and neuropsychi-
atry-psychology.
Genetic aetiology
CFS is occasionally seen in several family members and 
therefore there may be a familial predisposition or a genetic 
link to the disease. Hickie et al. [10] studied a popula-
tion of twins to evaluate genetic and environmental factors 
of prolonged fatigue. A genetic variance for fatigue were 
found even in 44%, however a considerable lower rate 
for other forms of psychological stress, as well as a negli-
gible difference of environmental factors influence on 
chronic fatigue. On the other hand, Cho et al. [11] have 
detected that although genetic predisposition is a factor 
in the development pf chronic fatigue, the environmen-
tal factors still play a predominant role. Clearly, further 
research is needed to determine precisely the relationship 
between these factors.
Immunologic aetiology
It can be said that most scientists consider CSF to be the 
result of immune system response to different known or 
unknown triggers, such as infective causes, various vaso-
active peptides, etc. [12]. In numerous studies the loss of 
immunological control or tolerance has been attributed to 
the increased activity of proinflammatory cytokines, NK 
cells dysfunction and the subsequent loss of coordination 
between innate and acquired immunity, and the reactiva-
tion of various latent infections, such as Epstein Barr virus 
(EBV) infection [13, 14].
Several mechanisms that decrease NK function have 
been evaluated; decreased potency of NK cells subpopula-
tion, decreased levels of NK cells modulating cytokines or 
the presence of various inhibition factors [15, 16].
So far, the most precise mechanism of NK cell damage 
was described in a study by Maher who registered a 
decrease in perforin concentration, a lytic protein of NK 
cells suggesting that in future this protein could be also 
used as a diagnostic marker [17].
The third group of authors advocating the immunolog-
ical model has studied disorders of T lymphocyte subpop-
ulation activity disorders and the decrease of antibody-
dependent cell-mediated cytotoxicity [17]. In addition, the 
studies involved the evaluation of other cytokine dereg-
ulation models with a still undefined role of proinflam-
matory cytokine concentration increase or decrease [18].
Recent studies have shown disorders of B lymphocytes 
function with decreased levels of IgG 1 and IgG 3 and 
increased levels of CD20+CD5+ lymphocytes in CFS [17]. 
A study by Maes and al. [19] disclosed a presence of IgM 
induced immune response to membrane lipid compo-
nents released under the influence of lipid peroxidation 
and NO-modified amino acids implying the role of oxida-
tive stress. These findings could explain the decrease of 
antiviral potential in CNF patients. Another potential 
cause of impaired antiviral defence mechanisms in CFS is 
explained by the alteration of 2-5 oligoadenilate synthe-
sis due to interferon by the production of L-cell RNA [20, 
21, 22].
Infective aetiology
Infections have long been considered to be the most impor-
tant participating factor in the development of CFS. There 
are two reasons for this. First, CFS is often diagnosed during 
a follow- up exam after an acute EBV infection, influenza 
virus, Parvovirus B19, enteroviruses, Coxsackie B, Herpes 
simplex virus 4,6 or 7, Brucella spp. or Chlamydia pneu-
moniae. Secondly CFS is often seen in endemic regions 
which can be associated with Lyme disease, Q fever, Ross 
River fever, Nypah encephalitis etc. [23].
Of all infective causes, EBV has been most frequently 
studied, so that in the 1990s “chronic EBV infection” was in 
fact a synonym for CFS which was later completely aban-
doned [24-29]. Recent studies on the roles of viral infection 
in CFS aetiology speak in favour of a possible VP1, RNA 
and non-cytopathogenic enteroviral infections detected 
in patients’ gastric mucosa biopsy specimens. The authors 
suggest that a significant number of CFS patients may have 
a chronic disseminated non-cytopathogenic for of entero-
viral infection which could be diagnosed by biopsy [29]. 
Also, there is a most recent study on a possible influence 
of XMRV retroviral infection, as this virus was detected 
in blood cells of CFS patients [30].
Endocrinological and metabolic disorders
One of the modern theories on the pathogenesis of CFS 
deals with disorders in the hypothalamic–pituitary–adrenal 
axis (HPA). A decreased activity of HPA due to increased 
antiadrenocortical antibodies has been found in some 
CFS patients [31]. Other metabolic disorders found in 
CFS include low levels of magnesium, arachidonic acid, L 
carnitine, dehydroepiandrosterone sulfate etc. [10].
Neuropsychiatry – psychology
It is very difficult to distinguish psychopathologic phenom-
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they could be coexisting conditions. In two studies done 
by Rangel et al. [10] and Endicott [32] there is convinc-
ing evidence that persons who were under increased stress 
(prenatally, in childhood or during adolescence) are at an 
increased risk of CFS. There is also a clear relationship 
between sleep disorders and CFS, regardless of psychiat-
ric co-morbidities [33].
DEFINITION OF CFS AND CRITERIA 
FOR ITS DIAGNOSIS
CFS is characterized by profound and long-lasting fatigue. 
Although fatigue is present in many diseases, in CFS it is 
a specific symptom without visible organic causes [34].
CFS was defined by the CDC in 1988 and revised in 
2001 and again in 2003 [35]. According to this definition, 
CFS is characterized by profound, debilitating fatigue 
which is persistent or recurrent, lasts for at least 6 months, 
not caused by physical strain and does not subside after 
rest, which finally results in the decrease of life activities; 
occupational, personal and social [36-40].
CDC criteria of CFS diagnosis are:
1. Unexplained, persistent and debilitating fatigue that 
does not withdraw after rest, which lowers the level of 
average daily activity by 50% continually over a 6-month 
period, with a healthy patient before onset.
2. Beside fatigue, the patients present four or more of 
the following symptoms which are persistent or occasional 
over a minimal period of 6 months, and can occur prior 
to fatigue: impaired memory or concentration, post-exer-
tion malaise (extreme, prolonged exhaustion and exacerba-
tion of symptoms following physical or mental exertion), 
non-refreshing sleep, muscle pain, multi-joint pain without 
swelling or redness, headaches of a new type and severity, 
localization or severity, frequent or recurring sore throat, 
tender cervical or auxiliary lymph nodes.
Less often other symptoms could be present, such as 
increased thirst, recurrent infection of oropharyngeal or 
urogenital regions, allergic reactions, night sweats, malaise, 
paresis and premenstrual syndrome [41].
Although CFS criteria were revised in 2003, the American 
version insists more on physical symptoms, which partially 
prejudices the hypothesis that CNF is basically an immu-
nological disorder. On the other hand, the Oxford’s crite-
ria are more focused on the presence of myalgia, mood and 
sleep disorders [36].
Figure 1. Algorithm for Evaluating Chronic Fatigue Syndrome (CFS)
FATIGUE
Infectious diseases
Endocrinologic/metabolism disorders
Immunologic/rheumatologic disorders
Haematologic/oncologic disorders
Psychiatric disorders
Debilitating fatigue (major criteria)
+
Four or more minor criteria present for at least 6 months
Impaired memory or concentration post-exeretional malaise
Unrefreshing sleep
Muscle pain
Multijoing pain
Headaches (new type or severity)
Sore throat (frequent or recurring)
Tender cervical or axillary lymph nodes
Detailed history and exam, laboratory tests: urinalysis, total protein, glucose, CRP, electrolytes, 
complete blood count with leukocyte differential, alkaline phosphatase, creatinine, urea, albumin, 
antinuclear antibody and rheumatoid factor,globulin, calcium, ALT, AST, thyroid hormones
Positive findings Negative findings
CHRONIC FATIGUE SYNDROME
Refferal to a specialist Fatigue of unknown origin
Specific diagnosis >6 months259
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Physical examination of a CFS patient can be positive 
for tender cervical lymph nodes, sore throat, hypotension, 
orthostatic hypotension, mild or slightly increased fever, 
tachycardia and occasionally a positive Romberg test [3].
Defined criteria for exclusion of CFS criteria that are the 
following: current unresolved condition or disease that can 
cause fatigue, psychotic, melancholic or bipolar depression 
(excluding uncomplicated minor depression), psychotic 
disorders, schizophrenia, dementia, anorexia or bulimia 
nervosa, alcohol or drug abuse, obesity.
CFS diagnosis is very complex, particularly because 
the symptoms can be very similar to other conditions like 
fibromyalgia, Sjörgen syndrome, Gulf war syndrome etc. 
[42]. At the moment, the diagnosis is based on clinical 
criteria by excluding organic and psychiatric disorders [43]. 
That is why establishing a diagnosis requires a multidis-
ciplinary approach and collaboration between different 
specialists including a psychiatrist and a psychologist.
Because fatigue is the leading symptom in CFS, there 
have been many attempts to measure its levels. One of the 
most widely used methods is the Fibro Fatigue Scale. The 
scale was primarily designed for comparison of different 
treatment options. It involves a six grade scale containing 
12 variables: pain of entire body, muscle tension, joint pain, 
fatigue, concentration and concentration and memory 
disorders, increased sensitivity, sadness (depressive mood), 
sleep disorders, autonomic disorders, headaches and intes-
tinal disorders [44, 45]. A detailed illness history is the 
most important part of the diagnosis and demystification 
of this up-to-now unclarified disease. The saying that a 
meticulous illness history taken from the patient makes 
50% of diagnosis is completely true in regard to CFS. An 
appropriate algorithm for evaluating CFS is s hown in 
Figure 1.
LABORATORY TESTS FOR CFS
There is no specific diagnostic laboratory test for CFS [43]. 
Many routine laboratory tests are a part of CFS diagnostic 
protocol, because it is necessary to exclude organic disor-
ders characterized by fatigue (cardiovascular diseases, 
tumours, immunological, endocrine and haematological 
disorders, infectious diseases). After these preliminary 
tests, only a working diagnosis of CFS can be established. In 
order to give a definite diagnosis other, more precise tests 
should be done, such as serological tests for viruses (ELISA 
IgM and IgG Cytomegalovirus, EBV, Herpes simplex virus 
6 Coxsackie, HIV), tests for chemicals and toxins, etc. [46]. 
In order to assess HPA levels of cortisone, DHEA, somato-
medin C, estrogen, melatonin, arginine, vasopressin, sero-
tonin and ACTH should be determined [47, 48].
THERAPY
Even 31 different therapies for CFS can involve about 350 
available meta-analyses [34, 49].
Because there is no consensus on aetiology, therapeutic 
options are focused on symptoms relief, regain the patient’s 
strength and functioning.
It is not uncommon for CFS patients to self-medicate, 
as the condition is often misdiagnosed and mistreated. On 
the other hand, some patients are desperate to find the right 
physician and are willing to try any kind of therapy, often 
with little success. Both groups of CFS patients suffer of 
fatigue for years, while suffering becomes an integrated part 
of their everyday working, social and personal activities.
There is no specific aetiological treatment for CFS. If 
a current infection is definitively confirmed the diagno-
sis of CFS is discarded and a specific antiviral or antibac-
terial therapy can be administered [50, 51].
Nonsteroidal antiinflammatory drugs and other analge-
sics can be used to treat pain and suppress inflammatory 
response. Hydrocortisone therapy may be used in some 
patients when there is evidence of HPA disorder in order to 
decrease DHEA levels. Still, because of serious side effects, 
as for example, suprarenal suppression, hydrocortisone is 
not used routinely [50].
The use of antidepressants and antianxiety agents has 
shown as efficient in relieving psychopathologic symp-
tomes in almost all studies [51-54].
Cognitive behavioural therapy and, to a lesser degree, 
some other psychotherapeutic modalities have shown 
most promising results in relieving symptoms of CFS [34, 
52]. Dietary supplementation with antioxidants is also 
supported by advanced medicine due to its potentially 
positive effects on the neutralization of free radicals, and 
maintaining oxy-redox homeostasis in CFS patients [46, 
55, 56]. Also, supplementation with omega 3 fatty acids 
has been shown to reduce the concentration of omega-6 
unsaturated fatty acids in erythrocyte membranes [57].
In several meta-analyses long-lasting complex physical 
rehabilitation and kinesitherapy combined with cognitive 
behavioural therapy have shown to be the best therapeu-
tic option for CFS patients. Physical activity has shown to 
improve oxygen delivery, which in turn relieves some of 
the symptoms [58, 59, 60].
CONCLUSION
The up-to-date problem of CFS symptomatology research 
presents variations in the methods of data collection and 
analysis in different countries and regions. It is certain 
that CFS patients should be diagnosed more efficiently. 
In this a contribution would be certainly made once the 
term “chronic fatigue” is replaced by another, better term 
for this profoundly devastating condition [41]. According 
to Edward Conley, the author of America Exhausted, at 
least 50% of CFS patients do not fit the CDC criteria, which 
certainly does not mean that these patients are healthy [36].
There are three priorities regarding CFS: understanding 
pathogenesis, development of a diagnostic test (protocol) 
and achieving efficient treatment. Although an in depth 
analysis of CFS patients’ mortality has not yet been carried 260 Brkić S. et al. Chronic Fatigue Syndrome
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out, there is increasing evidence of increased suicidal 
tendencies in these patients.
At the moment, there are three existing priorities in 
the field of CFS research; understanding of pathogene-
sis, development of a diagnostic test and achievement of 
efficient treatment [50]. The detailed studies of mortality 
among patients with fatigue and persons with CFS have 
not been conducted yet, but several resources report that 
CFS is associated with increased risk of suicide [25].
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КРАТАК САДРЖАЈ
Син дром  хро нич ног  умо ра  (СХУ)  је  те жак,  оне спо со бља ва-
ју ћи умор ко ји тра је бар шест ме се ци и до во ди до зна чај ног 
по ре ме ћа ја по слов ног, лич ног, дру штве ног и обра зов ног ста-
ња.  СХУ  се  у  на шој  сре ди ни  рет ко  ди јаг но сти ку је,  иако  нас 
сва ко днев ни рад са па ци јен ти ма уве ра ва да осо ба са симп-
то ми ма СХУ има мно го. И по ред чи ње ни це да су ин ци ден ци ја 
и пре ва лен ци ја СХУ не по зна те, зна се да се ово ста ње углав-
н о м   ј а  в љ а   к о д   р а д  н о   а к  т и в  н е   п о  п у  л а  ц и  ј е   с а   п р е  д о  м и  н а  ц и -
јом  же на  у  ге не ра тив ној  до би.  Пр ви  по да ци  о  СХУ  да ти ра ју 
од пре 400 го ди на, али ње го ва још не раз ја шње на ети о па то-
г е  н е  з а  и  д а  љ е  з а  о  к у  п љ а  п а  ж њу  н а у ч  н е  ј а в  н о  с т и .  У  д о  с т у п  н о ј  
л и  т е  р а  т у  р и  п о  м и  њ е  с е  о к о  8 0  р а з  л и  ч и  т и х  е т и  о  л о  ш к и х  ф а к -
то ра  ко ји  се  мо гу  раз вр ста ти  у  пет  гру па:  ге нет ски,  иму но-
л о  ш к и ,   и н  ф е к  т и в  н и ,   е н  д о  к р и  н о  л о  ш к и   и   н е  у  р о п  с и  х и  ј а  т р и ј -
ско-пси хо ло шки  ети о ло шки  фак то ри.  Ди јаг но за  СХУ  се  ис-
кљу чи во по ста вља per ex clu si o nem ор ган ских и пси хи ја триј-
с к и х  п о  р е  м е  ћ а  ј а ,  ш т о  з а х  т е  в а  м у л  т и  д и  с ц и  п л и  н а р  н и  п р и  с т у п  
овом про бле му. С об зи ром на то да се син дром че сто по гре-
ш н о  д и  ј а г  н о  с т и  к у  ј е ,  а  б о  л е  с н и  ц и  л о  ш е  и л и  н е  а  д е  к в а т  н о  л е -
че,  не рет ко  се  де ша ва  да  осо бе  са  СХУ  узи ма ју  те ра пи ју  на 
с в о  ј у   р у  к у.   Та  к о  ђ е ,   о в и   б о  л е  с н и  ц и   г о  д и  н а  м а   ж и  в е   с   т е  ш к и м  
умо ром, ко ји по ста је део њих и њи хо ве сва ко дне ви це. За то 
се у овом тре нут ку мо гу из дво ји ти три при о ри те та у по гле-
д у   л е  ч е  њ а   о д   С Х У:   р а з  у  м е  в а  њ е   п а  т о  г е  н е  з е ,   р а з  в о ј   д и  ј а г  н о -
стич ких  те сто ва  и  по сти за ње  ефи ка сног  про гра ма  ле че ња.
Кључне речи: синдром хроничног умора; етиологија; ди-
јаг ноза
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